Hemepath               SmartGenTM          SmartPathTM

Requisition

NEWS

Precipio and Transgenomic announce experts from Yale and Harvard joining new scientific board to support merged company's growth initiatives

June 2017 - Precipio Diagnostics and Transgenomic, Inc. (OTCQB: TBIOD) today announced the formation of a new Scientific Advisory Board (SAB) in anticipation of their previously disclosed merger. The new SAB, which will become effective on the closing of the merger, is being established to provide scientific and technical guidance and expertise to the combined company’s management and board of directors in support of current and future business initiatives. SAB members include Dr. Jeffrey Sklar of the Yale University School of Medicine, Dr. Mike Makrigiorgos of Harvard Medical School and the Dana-Farber Cancer Institute, and Dr. Gil Mor of the Yale University School of Medicine.

 

Precipio Diagnostics Renews its Exclusive Agreement with Yale School of Medicine for an Additional Five Years

April 2017 - Precipio Diagnostics, a company harnessing the experience, knowledge and expertise of academic-level pathology to deliver diagnostic accuracy to physicians and patients worldwide, announced that it has signed an exclusive agreement with Yale School of Medicine for an additional five years, after concluding its initial five year term.

 

Precipio Diagnostics and Transgenomic Announce Planned Merger

October 2016 - Transgenomic, Inc. (NASDAQ: TBIO), and privately-held Precipio Diagnostics, LLC today announced entry into a merger agreement, pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic, and Transgenomic will be renamed Precipio, Inc.

 

• Precipio enters into partnership agreement with MyGeneCounsel

June 2015 - Precipio Diagnostics and MyGeneCounsel have entered into an agreement to integrate MyGeneCounsel's unique platform of genomic interpretation, into its SmartGen™ offering. Precipio will serve as MyGeneCounsel's first charter partner, collaborating to offer valuable customer insight and feedback, helping to shape the platform. Precipio will be the first reference laboratory to offer MyGeneCounsel's platform to its customers worldwide, bringing the expertise of the MyGeneCounsel team to the benefit of oncologists.

 

• Precipio enters into a sales & marketing agreement with Columbia University

February 2015 - Precipio Diagnostics and Columbia University have entered into an agreement to market Next Generation Sequencing (NGS) tests developed in Columbia's Personalized Genomic Medicine Laboratory. Precipio will be able offer Columbia's advanced tests to its customers worldwide, bringing the expertise of Columbia's PGL to the benefit of oncologists.

 

• Precipio enters into a sales & marketing agreement with University of Pennsylvania

February 2015 - Precipio Diagnostics and University of Pennsylvania have entered into an agreement to market Next Generation Sequencing (NGS) tests developed at University of Pennsylvania's Center for Personalized Diagnostics (CPD). Precipio will be able offer UPenn's advanced tests to its customers worldwide, bringing the expertise of UPenn's CPD to the benefit of oncologists.

 

• Precipio enters into distribution agreement with Megapharm, Ltd. in Israel

March 2014 - Precipio Diagnostics and Megapharm, Ltd. have entered into an agreement to market Precipio's SmartGen™ offering to oncologists and hospitals throughout Israel. Megapharm's team brings extensive access to a network of oncologists and hospitals in this market.

 

• Precipio enters into distribution agreement with Raffles Medical Group in Singapore

November 2014 - Precipio Diagnostics and Raffles Medical Group have entered into an agreement to market Precipio's SmartGen™ offering in various markets throughout Asia. The Raffles network of hospitals and various partnerships brings a strong presence within these markets, and provides direct access to oncologists who are seeking the most advanced tests available to offer to their patients.

 

• Precipio enters into sales & marketing agreement with Rosetta Genomics

April 2014 - Precipio Diagnostics and Rosetta Genomics (NASDAQ: ROSG) have entered into a co-promotional commercial partnership for the sales and marketing of Precipio's oncology tests in various markets throughout the US.

 

• Precipio enters into distribution agreement with Farotech Enterprises in Greece

February 2014 - Precipio Diagnostics and Farotech Enterprises Ltd. have entered into an agreement to market Precipio's SmartGen™ offering in various markets throughout Europe. Farotech's team brings extensive access to a network of oncologists and hospitals in several markets throughout Europe.

 

Precipio enters into a sales & marketing agreement with Baylor College of Medicine

January 2014 - Precipio Diagnostics and Baylor College of Medicine have entered into an agreement to market Baylor's Medical Genetics Laboratory's Next Generation Sequencing (NGS) tests. Precipio will be able offer Baylor's advanced tests to its customers worldwide, bringing the expertise of Baylor's PGL to the benefit of oncologists. Baylor, a world renowned institution with significant expertise in genomics, was one of the institutions to lead the human genome project.

 

• Precipio enters into distribution agreement with Kindstar in China

November 2013 - Precipio Diagnostics and Wuhan Kindstar Diagnostics Co., Ltd. have entered into an agreement to market Precipio's SmartPath™ 2nd opinion consultation offering in various markets throughout China. Kindstar is the largest reference laboratory in China, and serves a vast network of hospitals throughout China. It brings a strong presence within these markets, and provides direct access to oncologists who are seeking the most advanced pathology support available to offer to their patients.

 

• Precipio acquires exclusive worldwide license to patented ovarian cancer biomarker and commences development

March 2013 - Precipio Diagnostics has signed an agreement with Yale University Office of Collaborative Research (OCR) to acquire the exclusive worldwide license and subsequent commercial rights to a patented biomarker developed at Yale. The Biomarker will be further developed and validated at Precipio in collaboration with Yale faculty, and once commercialized, will serve as a therapeutic indicator to help predict patients' response to various chemotherapy agents used to treat ovarian tumors.

 

• Richard Sandberg joins Precipio's Board as an Advisor

May 2012 - Precipio Diagnostics has added Richard Sandberg to its Board, serving as a non-director advisor to the company's board of directors and management. Formerly the founder and CEO of Dianon, Mr. Sandberg brings extensive expertise and experience in the diagnostics industry.

 

Contact

International Locations

contact@precipiodx.com

Tel: +1.203.787.7888

Fax: +1.203.901.1289

4 Science Park

New Haven, CT 06511

USA

 

Pay My Bill

Privacy | Legal

© 2016 Precipio Diagnostics, All Rights Reserved.